A judge has approved a “disappointing” $25 million settlement in long-running class action litigation over the collapse of electronics retailer Dick Smith with claims worth hundreds of millions of dollars.
ASIC has fired back at iSignthis’ defence to the regulator’s claims that it violated the Corporations Act by not disclosing $3 million in one-off revenue related to integration agreements, saying it was not the job of its compliance officials to school the fintech on its disclosure obligations.
Construction company Clough Limited cannot claim over $15 million paid to employees for cancellation of their shares and options as a tax deduction, with a judge dismissing the Perth-based company’s appeal of a decision from the Commissioner of Taxation.
Doomed iron and steel giant Arrium attempted to stave off its inevitable $2.8 billion collapse and put off negotiating with its lenders until the last minute despite warnings from its legal and financial advisors, liquidators for the company told the court.
More than half of the $37.75 million settlement reached in a shareholder class action against aged care provider Estia Health will be left for distribution to group members if the settlement is approved at an upcoming hearing.
Australia’s merger laws are not fit for purpose and the current approach to merger control needs to be rebalanced, the head of the ACCC has said in setting down the regulator’s agenda for 2021.
Group members in a class action against Oculus Accounting may not receive a payout after the company’s insurers refused to indemnify it against claims alleging the accounting firm was negligent in prompting an investment in failed music streaming platform Guvera.
The Australian Competition and Consumer Commission has raised preliminary competition concerns about the proposed merger of insurance giants Aon and Willis Towers Watson to create the world’s largest insurance provider, following investigations in the US, Europe, Canada and New Zealand.
Allens has snagged two new heavy hitters from HWL Ebsworth to bolster its corporate team in Perth.
Multinational pharmaceutical company Dr Reddy’s has launched a lawsuit against a Melbourne biotechnology company’s directors as well as venture capital firm OneVentures, alleging they sold it dodgy lice treatment which was forecasted to make over US$100 million.